Pricing Log in Create free account
Saturday 17 October 2026 Export PLRX’s income statement to Excel — free account

Pliant Therapeutics, Inc.

PLRX Healthcare Biotechnology

Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022. In the quarter to June 2026, EPS grew 49.3% and free cash flow grew 68.6%, each against the same quarter a year earlier.

0.90 0.07 −7.22%
Market cap
$60.2M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
4/9
Altman Z
15.11
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.16
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — 4 — — — — — — — — —
Insider Ownership 2.63%

Capital & Financial Ratios $m

Market Cap 60.21
Revenue 5.03
Net Income (92.29)
Free Cash Flow (70.62)
Net Debt (158.10)
Current Ratio 9.90 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.95) (negative: loss-making)
P/S ratio 11.09 (above 10: high)
P/B ratio 0.38
Past 5Y EPS Growth —
This Y EPS Growth 41.07% (at or above 15%: strong)
Next Y EPS Growth 5.16%
Next Y revenue growth (13.67%) (below 0%: weak)
Next 5Y EPS Growth 23.86% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −14.3×, against a ten-year median of 37.1×; over the ten years it ranged from −38.3× in 2025 to 119× in 2023.
P/S against its own 10 years 4.15%
10-year low 10-year high
P/B against its own 10 years 6.13%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 494 356 191 158
Receivables — — — —
Inventory — — — —
Other — — 1 1
506 362 196 163
2023 2024 2025 Q'26
Payables 5 6 0 2
ST’ Debt — — — —
Other — — — —
29 33 16 16

Compound Annual Growth %

10y 5y 3y
Sales — — (66.44%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (8.53%) (16.69%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’23 1 0 — — 2
’22 1 5 1 2 10
’21 2 2 2 2 8
’20 29 4 5 4 42
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (19) (13) — — —
’25 (49) (41) (21) (18) (128)
’24 (30) (45) (32) (48) (156)
’23 (30) (25) (36) (25) (116)
’22 (20) (24) (18) (31) (95)
’21 (14) (19) (23) (20) (75)
’20 (13) 8 (16) (16) (37)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (19) (13) — — —
’25 (49) (41) (21) (18) (129)
’24 (32) (47) (33) (48) (159)
’23 (30) (25) (36) (25) (117)
’22 (21) (25) (19) (31) (96)
’21 (14) (20) (23) (20) (77)
’20 (13) 7 (16) (17) (39)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.32) (0.36) — — —
’25 (0.92) (0.71) (0.43) (0.38) (2.43)
’24 (0.78) (0.92) (0.95) (0.82) (3.47)
’23 (0.67) (0.70) (0.70) (0.69) (2.75)
’22 (0.78) (0.82) (0.65) (0.72) (2.94)
’21 (0.64) (0.64) (0.75) (0.68) (2.71)
’20 5.81 (1.39) (0.47) (0.54) (1.95)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 19.43 11.91 3.97 12.61 10.22 1.10

Analyst estimates 2026–2028

Powerpack
High — — — — 35.63 43.92 26.25 36.64 19.62 13.71
People
People Employees — — — 62 78 91 124 158 171 49
Revenue/emp, $m — — — 0.92 0.54 0.08 0.08 0.01 0.00 0.00
Income, $m
Income, $m Revenue — — — 57 42 8 10 2 — —
Gross margin, % — — 0.00 100.00 100.00 100.00 100.00 100.00 — —
EBT — — (30) (1) (42) (97) (123) (161) (210) (149)
EBT margin, % — — 0.00 (1.11) (99.32) (1,284.51) (1,273.32) (10,211.14) 0.00 0.00
Net income — 0 (30) (1) (42) (97) (123) (161) (210) (149)
Depreciation — — 1 1 1 3 0 (3) 5 6
Per share, $
Per share, $ Revenue — — 0.00 35.14 1.96 0.21 0.23 0.03 0.00 0.00
Earnings — — (25.98) (0.39) (1.95) (2.71) (2.94) (2.75) (3.47) (2.43)
Cash flow — — (24.31) (1.69) (1.75) (2.10) (2.25) (1.98) (2.57) (2.09)
Capex — — (1.99) (0.59) (0.07) (0.05) (0.04) (0.02) (0.06) 0.00
Free cash flow — — (26.30) (2.29) (1.82) (2.16) (2.29) (2.00) (2.63) (2.09)
Book value — — 52.02 67.75 13.26 5.55 7.46 8.07 5.02 2.95
Shares, m — — 1 2 21 36 42 59 61 61
Valuation, ×
Valuation, × P/E — — — 1.39 6.66 0.00 0.00 0.00 — —
P/S — — — 0.00 11.60 63.91 82.43 209.79 — —
P/B — — — 0.00 1.71 2.43 2.55 2.23 — —
EV/Sales — — — 0.00 4.98 38.12 49.26 113.47 — —
EV/FCF — — — 17.69 (5.36) (3.73) (4.95) (4.86) — —
Cash, $m
Cash, $m Operating cash flow — — (28) (3) (37) (75) (95) (116) (156) (128)
Capex — — (2) (1) (2) (2) (2) (1) (4) 0
Free cash flow — — (31) (4) (39) (77) (96) (117) (159) (129)
Balance, $m
Balance, $m Working capital — — 57 104 279 193 316 477 329 180
Total debt — — — — — 5 10 10 30 —
Net debt — — (61) (103) (277) (195) (321) (484) (326) (191)
Shareholders’ equity — — 61 110 283 199 313 474 304 181
Returns, %
Returns, % ROA — — (105.67) (7.39) (20.04) (37.64) (43.13) (37.40) (46.27) (48.01)
ROIC — — 0.00 (10.68) (422.05) (1,609.28) 0.00 0.00 0.00 0.00
ROE — — 47.58 9.28 (40.17) (40.35) (48.13) (41.00) (54.09) (61.55)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Jun 2023

Charts ten years each

Pliant Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CING Cingulate Inc. $63.8M — (loss-making) — — n/m −24.28% (below 0%: shrinking) 0.00% 0.00% Compare
FBIO Fortress Biotech, Inc. $63.7M 0.6× 1.1× +14.04% (above 0%: growing) n/m −115.37% (below 0%: shrinking) 67.18% (53.46%) Compare
APLM Apollomics Inc. $61.2M — (loss-making) — — 0.00% +76.08% (above 0%: growing) — — Compare
BMEA Biomea Fusion, Inc. $60.6M — (loss-making) — — n/m +47.80% (above 0%: growing) 0.00% 0.00% Compare
PLRX Pliant Therapeutics, Inc. $60.2M — (loss-making) — (loss-making) −95.03% (below 0%: shrinking) n/m +68.61% (above 0%: growing) 0.00% 0.00%
XLO Xilio Therapeutics, Inc. $59.4M — (loss-making) — (loss-making) +131.22% (above 0%: growing) n/m −26.23% (below 0%: shrinking) 100.00% (18.68%) Compare
GANX Gain Therapeutics, Inc. $58.1M — (loss-making) — (loss-making) +27.78% (above 0%: growing) n/m +8.22% (above 0%: growing) 0.00% 0.00% Compare
CNTB Connect Biopharma Holdings Limited Sponsored ADR $57.1M — (loss-making) — (loss-making) +296.56% (above 0%: growing) n/m −23.48% (below 0%: shrinking) 100.00% (635.98%) Compare
TENX Tenax Therapeutics, Inc. $56.5M — (loss-making) — −77.98% (below 0%: shrinking) n/m −125.93% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $60.0M — — +27.78% — −23.88% 0.00% 0.00%

All 614 Biotechnology stocks →

Pliant Therapeutics, Inc. (PLRX) key facts

  • Concern: Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022.
  • Pliant Therapeutics, Inc. (PLRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, PLRX traded at $0.90, a market capitalization of $60.2 million.
  • Return on equity was −61.6% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 15.11 (safe zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.

Pliant Therapeutics, Inc. (PLRX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/PLRX · Data as of Jun 30, 2023 · For information only; not investment advice. · © 2026 stockrow.com